9 results on '"Till, Brian G"'
Search Results
2. Recommendations for Clinical Trial Development in Mantle Cell Lymphoma.
- Author
-
Spurgeon, Stephen E., Till, Brian G., Martin, Peter, Goy, Andre H., Dreyling, Martin P., Gopal, Ajay K., LeBlanc, Michael, Leonard, John P., Friedberg, Jonathan W., Baizer, Lawrence, Little, Richard F., Kahl, Brad S., and Smith, Mitchell R.
- Subjects
- *
CLINICAL trials , *MANTLE cell lymphoma , *LYMPHOMA treatment , *STEM cell transplantation , *MEDICAL needs assessment , *HETEROGENEITY , *THERAPEUTICS , *CARCINOGENESIS , *ANTINEOPLASTIC agents , *BIOLOGICAL assay , *DRUG therapy , *EXPERIMENTAL design , *LYMPHOMAS , *RESEARCH funding - Abstract
Mantle cell lymphoma (MCL) comprises around 6% of all non-Hodgkin's lymphoma (NHL) diagnoses. In younger patients, age less than 60 to 65 years, aggressive induction often followed by consolidation with autologous stem cell transplant has suggested improved outcomes in this population. Less intensive therapies in older patients often followed by maintenance have been studied or are under active investigation. However, despite recent advances, MCL remains incurable, with a median overall survival of around five years. Patients with high-risk disease have particularly poor outcomes. Treatment varies widely across institutions, and to date no randomized trials comparing intensive vs less intensive approaches have been reported. Although recent data have highlighted the heterogeneity of MCL outcomes, patient assessment for treatment selection has largely been driven by patient age with little regard to fitness, disease biology, or disease risk. One critical advance is the finding that minimal residual disease status (MRD) after induction correlates with long-term outcomes. As such, its use as a potential end point could inform clinical trial design. In order to more rapidly improve the outcomes of MCL patients, clinical trials are needed that prospectively stratify patients on the basis of MCL biology and disease risk, incorporate novel agents, and use MRD to guide the need for additional therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
3. Phase II trial of R- CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601.
- Author
-
Till, Brian G., Li, Hongli, Bernstein, Steven H., Fisher, Richard I., Burack, W. Richard, Rimsza, Lisa M., Floyd, Justin D., DaSilva, Marco A., Moore, Dennis F., Pozdnyakova, Olga, Smith, Sonali M., LeBlanc, Michael, and Friedberg, Jonathan W.
- Subjects
- *
MANTLE cell lymphoma , *BORTEZOMIB , *CYCLOPHOSPHAMIDE , *PERIPHERAL neuropathy , *CANCER chemotherapy - Abstract
Bortezomib is active in mantle cell lymphoma ( MCL), with approval in upfront and relapsed settings. Given inevitable recurrence following induction chemoimmunotherapy, maintenance approaches are a rational strategy to improve clinical outcomes. We conducted a phase II study to evaluate the safety and efficacy of six cycles of R- CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) plus bortezomib (1·3 mg/m2 days 1 and 4 of 21 d cycles) followed by bortezomib maintenance (1·3 mg/m2 days 1, 4, 8, and 11 every 3 months for 2 years). Sixty-five eligible patients were enrolled. The treatment was well tolerated and toxicities were mainly haematological. The rate of grade ≥3 peripheral neuropathy was low (5%). With a median follow-up of 6·8 years, 2-year progression-free survival ( PFS) was 62%, and 2-year overall survival ( OS) was 85%. At 5 years, PFS was 28% and OS was 66%. MCL International Prognostic Index scores were significantly associated with 2-year PFS, but did not predict long-term (≥5-year) PFS. Baseline Ki-67 index was significantly associated with survival. Combination R- CHOP with bortezomib followed by maintenance bortezomib appears to improve outcomes compared historically with R- CHOP alone, with prolonged remissions in a subset of patients. These results suggest that inclusion of bortezomib with induction chemotherapy and/or maintenance is promising in MCL and warrants further exploration. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
4. High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphoma.
- Author
-
Cassaday, Ryan D., Stevenson, Philip A., Gooley, Theodore A., Chauncey, Thomas R., Pagel, John M., Rajendran, Joseph, Till, Brian G., Philip, Mary, Orozco, Johnnie J., Bensinger, William I., Holmberg, Leona A., Shustov, Andrei R., Green, Damian J., Smith, Stephen D., Libby, Edward N., Maloney, David G., Press, Oliver W., and Gopal, Ajay K.
- Subjects
STEM cell transplantation ,LYMPHOMA treatment ,MANTLE cell lymphoma ,THERAPEUTIC use of immunoglobulins ,CD20 antigen ,RADIOIMMUNOTHERAPY ,THERAPEUTICS - Abstract
Autologous stem cell transplant (ASCT) can improve outcomes for mantle cell lymphoma (MCL) patients, yet relapses are frequent. We hypothesized that high-dose anti-CD20 radioimmunotherapy (RIT)-based conditioning could improve results in this setting. We thus assessed 162 consecutive patients with MCL at our centre undergoing ASCT following high-dose RIT-based (n = 61) or standard (n = 101) conditioning. RIT patients were less likely to be in first remission (48% vs. 72%; P = 0.002), be in complete remission (CR) (26% vs. 61%; P < 0.001) and have chemosensitive disease (84% vs. 96%; P = 0.006). RIT-based conditioning was associated with a reduced risk of treatment failure [hazard ratio (HR) 0.40; P = 0.001] and mortality (HR 0.49; P = 0.01) after adjusting for these imbalances. This difference increased as disease status worsened (from CR to partial remission to stable/progressive disease), with respective HRs of 1.14, 0.53 and 0.04 for mortality, and 0.66, 0.36 and 0.14 for treatment failure. RIT-based conditioning appears to improve outcome following ASCT for MCL patients unable to achieve CR after controlling for imbalances in important risk factors. These data support the further study of RIT and radiation-based strategies in a risk-adapted approach to ASCT for persistent MCL. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
5. Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma.
- Author
-
Till, Brian G., Gooley, Theodore A., Crawford, Nathan, Gopal, Ajay K., Maloney, David G., Petersdorf, Stephen H., Pagel, John M., Holmberg, Leona, Bensinger, William, and Press, Oliver W.
- Subjects
- *
STEM cell transplantation , *CELL transplantation , *DISEASE remission , *TRANSPLANTATION of organs, tissues, etc. , *THERAPEUTICS , *CLINICAL medicine - Abstract
We analysed the outcomes of autologous stem cell transplantation (ASCT) following high-dose therapy with respect to remission status at the time of transplantation and induction regimen used in 56 consecutive patients with mantle cell lymphoma (MCL). Twenty-one patients received induction chemotherapy with HyperCVAD with or without rituximab (±R) followed by ASCT in first complete or partial remission (CR1/PR1), 15 received CHOP (±R) followed by ASCT in CR1/PR1 and 20 received ASCT following disease progression. Estimates of overall and progression-free survival (PFS) at 3 years among patients transplanted in CR1/PR1 were 93% and 63% compared with 46% and 36% for patients transplanted with relapsed/refractory disease, respectively. The hazard of mortality among patients transplanted with relapsed/refractory disease was 6.09 times that of patients transplanted in CR1/PR1 (P = 0.006). Patients in the CHOP (±R) group had a higher risk of failure for PFS compared with patients in the HyperCVAD (±R) group, though the difference did not reach statistical significance (hazard ratio 3.67, P = 0.11). These results suggest that ASCT in CR1/PR1 leads to improved survival outcomes for patients with MCL compared to ASCT with relapsed/refractory disease, and a HyperCVAD (±R) induction regimen may be associated with an improved PFS among patients transplanted in CR1/PR1. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
6. Total Body Irradiation Is Safe and Similarly Effective as Chemotherapy-Only Conditioning in Autologous Stem Cell Transplantation for Mantle Cell Lymphoma.
- Author
-
Tseng, Yolanda D., Stevenson, Philip A., Cassaday, Ryan D., Cowan, Andrew, Till, Brian G., Shadman, Mazyar, Graf, Solomon A., Ermoian, Ralph, Smith, Stephen D., Holmberg, Leona A., Press, Oliver W., and Gopal, Ajay K.
- Subjects
- *
MANTLE cell lymphoma , *STEM cell transplantation , *TOTAL body irradiation , *DISEASE remission , *CANCER chemotherapy , *TREATMENT effectiveness , *THERAPEUTICS - Abstract
Autologous stem cell transplant (ASCT) consolidation has become a standard approach for patients with mantle cell lymphoma (MCL), yet there is little consensus on the role of total body irradiation (TBI) as part of high-dose transplantation conditioning. We analyzed 75 consecutive patients with MCL who underwent ASCT at our institution between 2001 and 2011 with either TBI-based (n = 43) or carmustine, etoposide, cytarabine, melphalan (BEAM; n = 32) high-dose conditioning. Most patients (97%) had chemosensitive disease and underwent transplantation in first remission (89%). On univariate analysis, TBI conditioning was associated with a trend toward improved PFS (hazard ratio [HR], .53; 95% confidence interval [CI], .28-1.00; P = .052) and similar OS (HR, .59; 95% CI, .26-1.35; P = .21), with a median follow-up of 6.3 years in the TBI group and 6.6 years in the BEAM group. The 5-year PFS was 66% in the TBI group versus 52% in the BEAM group; OS was 82% versus 68%, respectively. However, on multivariate analysis, TBI-based conditioning was not significantly associated with PFS (HR, .57; 95% CI .24-1.34; P = .20), after controlling for age, disease status at ASCT, and receipt of post-transplantation rituximab maintenance. Likewise, early toxicity, nonrelapse mortality, and secondary malignancies were similar in the 2 groups. Our data suggest that both TBI and BEAM-based conditioning regimens remain viable conditioning options for patients with MCL undergoing ASCT. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
7. Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission.
- Author
-
Cowan, Andrew J., Stevenson, Philip A., Cassaday, Ryan D., Graf, Solomon A., Fromm, Jonathan R., Wu, David, Holmberg, Leona A., Till, Brian G., Chauncey, Thomas R., Smith, Stephen D., Philip, Mary, Orozco, Johnnie J., Shustov, Andrei R., Green, Damian J., IIILibby, Edward N., Bensinger, William I., Shadman, Mazyar, Maloney, David G., Press, Oliver W., and Gopal, Ajay K.
- Subjects
- *
MANTLE cell lymphoma , *CANCER chemotherapy , *CANCER treatment , *HUMAN ecology , *PATIENTS - Abstract
Autologous stem cell transplantation (ASCT) is standard therapy for mantle cell lymphoma (MCL) in remission after induction chemotherapy, with the best results for patients in complete remission (CR). We hypothesized that evaluation of minimal residual disease (MRD) before ASCT could further stratify outcomes for these patients. Patients with MCL who underwent ASCT in clinical CR between 1996 and 2011 with pretransplantation MRD testing were eligible. Presence of a clonal IgH rearrangement, t(11; 14) by PCR or positive flow cytometry from blood or bone marrow, was considered positive. An adjusted proportional hazards model for associations with progression-free (PFS) and overall survival (OS) was performed. Of 75 MCL patients in CR, 8 (11%) were MRD positive. MRD positivity was associated with shorter OS and PFS. The median OS for MRD-negative patients was not reached, with 82% survival at 5 years, whereas for the MRD-positive patients, median OS was 3.01 years (hazard ratio [HR], 4.04; P = .009), with a median follow-up of 5.1 years. The median PFS for MRD-negative patients was not reached with 75% PFS at 5 years, whereas for MRD-positive patients, it was 2.38 years (HR, 3.69; P = .002). MRD positivity is independently associated with poor outcomes after ASCT for MCL patients in CR. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
8. Specific Features Identify Patients with Relapsed or Refractory Mantle Cell Lymphoma Benefitting from Autologous Hematopoietic Cell Transplantation.
- Author
-
Cassaday, Ryan D., Guthrie, Katherine A., Budde, Elizabeth L., Thompson, Leslie, Till, Brian G., Press, Oliver W., Chauncey, Thomas R., Pagel, John M., Petersdorf, Stephen H., Palanca-Wessels, Maria Corinna, Philip, Mary, Bensinger, William I., Holmberg, Leona A., Shustov, Andrei, Green, Damian J., Libby, Edward N., Maloney, David G., and Gopal, Ajay K.
- Subjects
- *
LYMPHOMA treatment , *HEMATOPOIETIC stem cell transplantation , *HEALTH outcome assessment , *LYMPHOMAS , *HYPOTHESIS , *DISEASE progression , *PATIENTS - Abstract
Abstract: Outcomes with autologous hematopoietic cell transplantation (auto HCT) for relapsed and/or refractory mantle cell lymphoma (MCL) are typically poor. We hypothesized that certain factors could predict which patients experience a favorable outcome with this approach. We thus developed a predictive score from a cohort of 67 such patients using 3 factors independently associated with progression-free survival (PFS): (1) simplified Mantle Cell Lymphoma International Prognostic Index score before auto HCT (hazard ratio [HR], 2.9; P = .002); (2) B symptoms at diagnosis (HR, 2.7; P = .005); and (3) remission quotient, calculated by dividing the time, in months, from diagnosis to auto HCT by the number of prior treatments (HR, 1.4; P = .02). The estimated 5-year PFS for favorable-risk patients (n = 23) and unfavorable-risk patients (n = 44) were 58% (95% confidence interval [CI], 34% to 75%) and 15% (95% CI, 6% to 28%), respectively. These factors also independently predicted overall survival. In summary, we have defined 3 simple factors that can identify patients with relapsed/refractory MCL who derive a durable benefit from salvage auto HCT. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
9. Pretransplant Minimal Residual Disease (MRD) Positivity Independently Predicts Survival in a Unselected Cohort of Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission.
- Author
-
Cowan, Andrew J., Stevenson, Philip A., Cassaday, Ryan D., Graf, Solomon A., Holmberg, Leona, Fromm, Jonathan R., Till, Brian G., Wu, David, Chauncey, Thomas, Smith, Stephen D., Philip, Mary, Orozco, Johnnie J., Shustov, Andrei R., Green, Damian J., Libby, Edward N., Bensinger, William, Shadman, Mazyar, Maloney, David G., Press, Oliver W., and Gopal, Ajay K.
- Subjects
- *
MANTLE cell lymphoma , *AUTOGRAFTS , *STEM cell transplantation , *DISEASE remission , *CANCER research , *COHORT analysis - Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.